百宋一尘
07-29
$维立志博-B(09887)$
不管咋说,维立志博核心产品 LBL-024 领域尚无获批药物,还是临床空白,潜力是值得肯定的
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":461798706147664,"tweetId":"461798706147664","gmtCreate":1753762529981,"gmtModify":1753762531155,"author":{"id":4129795557139460,"idStr":"4129795557139460","authorId":4129795557139460,"authorIdStr":"4129795557139460","name":"百宋一尘","avatar":"https://static.tigerbbs.com/4fc1006043524972f4dc052b8cb2ed5f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><a href=\"https://laohu8.com/S/09887\">$维立志博-B(09887)$</a> 不管咋说,维立志博核心产品 LBL-024 领域尚无获批药物,还是临床空白,潜力是值得肯定的</body></html>","htmlText":"<html><head></head><body><a href=\"https://laohu8.com/S/09887\">$维立志博-B(09887)$</a> 不管咋说,维立志博核心产品 LBL-024 领域尚无获批药物,还是临床空白,潜力是值得肯定的</body></html>","text":"$维立志博-B(09887)$ 不管咋说,维立志博核心产品 LBL-024 领域尚无获批药物,还是临床空白,潜力是值得肯定的","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/461798706147664","repostId":0,"isVote":1,"tweetType":1,"viewCount":536,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["09887"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":97,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/461798706147664"}
精彩评论